Fedyanin, M. Y., & Tsukanov, A. S. (2025). Letter to the Editor Regarding the Article by the Authors: I.N. Fomin and S.P. Kovalenko "Which Minor KRAS Gene should be Analyzed in Colorectal Cancer?”. Voprosy Onkologii, 71(2), OF–2275. https://doi.org/10.37469/0507-3758-2025-71-2-OF-2275

Abstract

The Letter to the Editor provides comments on the article by I.N. Fomin and S.P. Kovalenko "Which minor KRAS gene should be analyzed in colorectal cancer?” by experts from the working group on the development and revision of clinical guidelines for the treatment of colorectal cancer. The authors reviewed both molecular genetic and clinical aspects.

https://doi.org/10.37469/0507-3758-2025-71-2-OF-2275

##article.numberofdownloads## 20

##article.numberofviews## 57

pdf (Русский)

References

Фомин И.Н., Коваленко С.П. Какие минорные мутации необходимо анализировать в гене KRAS в клетках опухоли при колоректальном раке? Вопросы онкологии. 2025; 71 (1).-DOI: 10.37469/0507-3758-2025-71-1-OF-2188. [Fomin I.N., Kovalenko S.P. What minor KRAS mutations should be analyzed in colorectal cancer? Voprosy Onkologii = Problems in Oncology. 2025; 71(1).-DOI: 10.37469/0507-3758-2025-71-1-OF-2188 (In Rus)].

de Langen A., Johnson M., Mazieres J., et al. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial. Lancet. 2023; 401 (10378): 733-746.-DOI: 10.1016/S0140-6736(23)00221-0.

Fakih M., Salvatore L., Esaki T., et al. Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C. N Engl J Med. 2023; 389(23): 2125-2139.-DOI: 10.1056/NEJMoa2308795

Martianov A., Mitiushkina N., Ershova A., et al. KRAS, NRAS, BRAF, HER2 and MSI Status in a Large Consecutive Series of Colorectal Carcinomas. Int J Mol Sci. 2023; 24(5): 4868.-DOI: 10.3390/ijms24054868.

Федянин М.Ю., Эльснукаева Х.Х.-М., Демидова И.А., et al. Колоректальный рак с мутацией в гене BRAF в Российской Федерации: эпидемиология и клинические особенности. Результаты многоцентрового исследования. Медицинский совет. 2021; (4S): 52-63.-DOI: 10.21518/2079-701X-2021-4S-52-63. [Fedyanin M., Ehlsnukaeva Kh., Demidova I.., et al. Incidence and prognostic factors in patents (pts) with mutant BRAF (mBRAF) metastatic colorectal cancer (mCRC) in Russia. Meditsinskiy sovet = Medical Council. 2021; (4S): 52-63.-DOI: 10.21518/2079-701X-2021-4S-52-63 (In Rus)].

Garrido-Laguna I., Wolpin B.M., Park W., et al. Safety, efficacy, and on-treatment circulating tumor DNA (ctDNA) changes from a phase 1 study of RMC-6236, a RAS(ON) multi-selective, tri-complex inhibitor, in patients with RAS mutant pancreatic ductal adenocarcinoma (PDAC). J Clin Oncol. 2025; 43(4_suppl): 722-722.-DOI: 10.1200/jco.2025.43.4_suppl.722.

Loree J.M., Wang Y., Syed M.A., et al. Clinical and functional characterization of AtypicalKRAS/NRASMutations in metastatic colorectal cancer. Clin Cancer Res. 2021; 27(16): 4587-98.-DOI: 10.1158/1078-0432.ccr-21-0180.

NCCN Guidelines Version 1.2025 Colon Cancer.-URL: https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf (13.02.2025).

Shitara K., Muro K., Watanabe J., et al. Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancer. Nat Med. 2024; 30(3): 730-9.-DOI: 10.1038/s41591-023-02791-w.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Letter to the Editor Regarding the Article by the Authors: I.N. Fomin and S.P. Kovalenko "Which Minor KRAS Gene should be Analyzed in Colorectal Cancer?”

Keywords

How to Cite

Abstract

References

Most read articles by the same author(s)